The research aimed to study the effect of ch-OSA® on bone collagen formation and bone density.
WHAT WE FOUND
Researchers found that ch-OSA® had a positive effect on bone formation markers. PINP (procollagen type I N-terminal propeptide) increased by 15% after 12 months in women who took ch-OSA® with calcium and vitamin D, compared to women taking calcium and vitamin D alone. (PINP is the most sensitive marker for bone collagen formation and is an early marker of bone formation. )
As well, women who were osteopenic in both the lumbar and the hip were found to have a 2% higher bone mineral density at the critical hip region compared to women in the placebo group. (2% is not only statistically significant but also clinically relevant.)
Compared to the control group, the participants taking ch-OSA® were measured to have:
2% higher bone mineral density at the hip
15% increase in bone collagen formation (PINP)
The participants were 184 Caucasian women who were mostly post-menopausal, with an average age of around 60. All were healthy, but with documented osteopenia at the lumbar spine (that is, with a T-score of < -1.5).
Figure 1: Bone collagen formation marker PINP (procollagen type I N-terminal propeptide) in osteopenic and osteoporotic women who took ch-OSA®, versus the control group.
Figure 2: The change in bone mineral density at the hip in osteopenic women who took ch-OSA®, versus the control group.
Researchers found that combining oral doses of ch-OSA® with calcium and vitamin D3 is not only safe, but has a potentially beneficial effect on bone formation, especially bone collagen, and possibly also on bone mineral density.